The role of mLOY in giant cell arteritis
This Medudy "Expert Opinion" is a video tutorial for physicians on "The role of mLOY in giant cell arteritis" presented by Dr. Peer Aries, rheumatologist and immunologist at the Immunologikum in Hamburg. New findings on the role of mosaic loss of the Y chromosome (mLOY) in giant cell arteritis will be presented. A clinical case will be discussed and the current study situation [...]
Infections in immunocompromised patients
This Medudy Expert Opinion is a video tutorial for physicians on the topic of "Infections in immunocompromised patients" presented by Dr. Peer Aries, head of the Immunologikum in Hamburg, a specialist center for rheumatology and immunology. Patients with autoimmune diseases undergoing immunosuppressive treatment have a significantly increased risk of serious infections and infection-related deaths. Patient-related and therapy-related risk factors are discussed, [...]
Guideline-Directed Medical Therapy in Heart Failure: Urgency Across the Ejection Fraction Spectrum
This Medudy course is a video tutorial for physicians on the topic "Guideline-based therapy of heart failure: need for action across the entire spectrum of ejection fraction". Heart failure is a progressive, life-threatening disease that remains one of the leading causes of hospitalization and death worldwide. Despite significant therapeutic advances, treatment success remains poor. [...]
mHSPC - Metastatic hormone-sensitive prostate cancer
This is a Medudy Master Series on prostate cancer. This module highlights the key aspects of metastatic hormone-sensitive prostate cancer (mHSPC) and is presented by Prof. Dr. Axel Merseburger, Director of the Department of Urology at the Lübeck Campus of the University Medical Center Schleswig-Holstein. The course is divided into four parts: The first part deals with the epidemiology and staging [...]
Guideline-based therapy of heart failure: need for action across the entire spectrum of ejection fraction
This Medudy course is a video tutorial for physicians on the topic "Guideline-based therapy of heart failure: need for action across the entire spectrum of ejection fraction". Heart failure is a progressive, life-threatening disease that remains one of the leading causes of hospitalization and death worldwide. Despite significant therapeutic advances, treatment success remains poor. [...]
Urgency and opportunity in heart failure: High-intensity guideline-based therapy across the entire spectrum of ejection fraction
This Medudy course is a video tutorial for physicians on "Urgency and opportunity in heart failure: High-intensity guideline-based therapy across the ejection fraction spectrum". Heart failure is a growing health problem worldwide, characterized by high hospitalization rates and mortality comparable to cancer. Despite remarkable advances in treatment, the majority of [...]
mHSPC - Metastatic hormone-sensitive prostate cancer
This is a Medudy Master Series on prostate cancer. This module highlights the key aspects of metastatic hormone-sensitive prostate cancer (mHSPC) and is presented by Prof. Dr. Axel Merseburger, Director of the Department of Urology at the Lübeck Campus of the University Medical Center Schleswig-Holstein. The course is divided into four parts: The first part deals with the epidemiology and staging [...]
Biosimilars
The Medudy course on biosimilars, presented by Professor Axel Merseburger, Director of the Clinic for Urology at the University of Lübeck, provides practical knowledge on the development, approval and use of biosimilars in everyday clinical practice.Biosimilars are follow-on preparations of biologics which, due to their complex production in biological systems, are not identical copies, but only highly comparable products. [...]
CAR-T cell therapy for myasthenia gravis
CAR-T cell therapy has established itself as an effective treatment option in haematooncology, particularly for B-cell lymphomas. Due to its targeted mechanism of action, it is also increasingly coming into focus for autoimmune diseases - including myasthenia gravis. In this Expert Opinion, Prof. Dr. Dr. Dr. Sven G. Meuth explains why patients with myasthenia gravis benefit from targeted [...].
BiTEs in the treatment of myasthenia gravis
Bispecific antibodies or so-called BiTEs are able to connect T cells and B cells as target cells by simultaneously binding two proteins. The T cell is thus activated and leads to a precise depletion of the target cells. In this Expert Opinion, Prof. Dr. Dr. Dr. Sven G. Meuth explains why BiTEs represent a promising therapeutic approach [...].